Corporate real estate is emerging as a critical factor in how much value pharmaceutical buyers ultimately realize from acquiring sponsor-backed biotech companies, according to a recent CBRE analysis. The report notes that while acquired biotech platforms typically operate with smaller footprints and lean teams, they are often only partly absorbed into the parent company after closing.
This pattern has given rise to what CBRE describes as “stranding” in life sciences mergers and acquisitions. Stranding occurs when serial acquisitions create a growing collection of partially integrated entities, each maintaining different systems, processes and real estate arrangements. Financial reporting for these acquired businesses generally remains intact, but their day-to-day operations and real estate management are not fully brought into the enterprise model.
CBRE points to several operational warning signs of stranding. These include fragmented workplace management systems across the acquired portfolio, lease renewals that proceed without coordinated oversight, and uneven environmental and sustainability reporting practices. Over time, these issues introduce preventable risk tied directly to real estate decisions and obligations.
The firm estimates that such avoidable real estate-related risks can reach roughly 1% of deal value across serial acquisitions. For large organizations that are active consolidators in life sciences, the cumulative impact of this exposure can be considerable, potentially exceeding $100 million over multiple years.
Instead of defaulting to conventional post-merger actions such as consolidating operations or closing facilities, CBRE recommends that acquirers elevate CRE integration as a core workstream. The goal is to protect the scientific momentum, maintain team cohesion and preserve the operating distinctiveness that made the biotech an attractive target, while ensuring that it can function efficiently within the larger enterprise.
The report outlines a practical integration playbook. One priority is to document the acquired company’s real estate operations within the first 90 days after closing, giving the buyer a clear inventory of locations, leases, systems and responsibilities. Another is to schedule portfolio-wide reviews at 18- to 24-month intervals to surface integration gaps, rank remediation needs and codify standardized procedures that can be applied to future acquisitions.
CBRE emphasizes that buyers have a limited window following each transaction to embed these practices before legacy approaches become entrenched. Moving early allows acquirers to align real estate strategy with the deal thesis without disrupting the scientific work that underpins product pipelines.
For life sciences consolidators that implement CRE integration best practices, the payoff can include stronger long-term value preservation from M&A, reduced operational complexity and more consistent governance across multi-asset portfolios. In a sector where serial acquisitions are common and R&D capabilities drive enterprise value, managing real estate as a strategic integration lever rather than a back-office function may increasingly influence overall deal performance.
